{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:09Z","timestamp":1747181169407,"version":"3.40.5"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,26]]},"abstract":"<jats:p>Anoikis is considered strongly associated with a biological procession of tumors. Herein, we utilized anoikis-related genes (ARGs) to predict the prognosis and immunotherapeutic efficacy for skin cutaneous melanoma (SKCM). RNA-seq data were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. After dividing patients into novel subtypes based on the expression of prognostic ARGs, K\u2013M survival was conducted to compare the survival status. Subsequently, differentially expressed ARGs were identified and the predictive model was established. The predictive effects were validated using the areas under the curve about the receiver operating characteristic. Moreover, tumor mutation burden, the enriched functional pathway, immune cells and functions, and the immunotherapeutic response were also analyzed and compared. The distribution of model genes at cell level was visualized by the single-cell seq with tumor immune single-cell hub database. Patients of The Cancer Genome Atlas\u2013SKCM cohort were divided into 2 clusters, the cluster 1 performed a better prognosis. Cluster 2 was more enriched in metabolism-related pathways whereas cluster 1 was more associated with immune pathways. A predictive risk model was established with 6 ARGs, showing the areas under the curves of 1-year, 3-year, and 5-year ROC were 0.715, 0,720, and 0.731, respectively. Moreover, risk score was negatively associated with tumor mutation burden and immune-related pathways enrichment. In addition, patients with high-risk scores performed immunosuppressive status but the decreasing scores enhanced immune cell infiltration, immune function activation, and immunotherapeutic response. In this study, we established a novel signature in predicting prognosis and immunotherapy. It can be considered reliable to formulate the complex treatment for SKCM patients.<\/jats:p>","DOI":"10.1097\/md.0000000000037900","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T18:11:58Z","timestamp":1714155118000},"page":"e37900","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Identification of an anoikis-related gene signature and characterization of immune infiltration in skin cutaneous melanoma"],"prefix":"10.1097","volume":"103","author":[{"given":"Ziqian","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-9365","authenticated-orcid":false,"given":"Juntao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment.","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJMsb2019760","article-title":"The rapid rise in cutaneous melanoma diagnoses.","volume":"384","author":"Welch","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"395","DOI":"10.6004\/jnccn.2013.0055","article-title":"Melanoma, version 2.2013: featured updates to the NCCN guidelines.","volume":"11","author":"Coit","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fimmu.2015.00046","article-title":"Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.","volume":"6","author":"Aris","year":"2015","journal-title":"Front Immunol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3892\/ijo.2020.5088","article-title":"Cutaneous melanoma and the immunotherapy revolution (Review).","volume":"57","author":"Leonardi","year":"2020","journal-title":"Int J Oncol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy.","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma.","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3390\/cancers11101472","article-title":"Current perspectives in cancer immunotherapy.","volume":"11","author":"Christofi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0955-0674(00)00251-9","article-title":"Anoikis mechanisms.","volume":"13","author":"Frisch","year":"2001","journal-title":"Curr Opin Cell Biol"},{"issue":"Suppl 2","key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/sj.cdd.4401723","article-title":"Anoikis.","volume":"12","author":"Gilmore","year":"2005","journal-title":"Cell Death Differ"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/path.3000","article-title":"Anoikis: an emerging hallmark in health and diseases.","volume":"226","author":"Taddei","year":"2012","journal-title":"J Pathol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1073\/pnas.91.19.8856","article-title":"Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen.","volume":"91","author":"Montgomery","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1126\/science.1071553","article-title":"The Fas signaling pathway: more than a paradigm.","volume":"296","author":"Wajant","year":"2002","journal-title":"Science"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/20959","article-title":"Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC.","volume":"399","author":"Shimizu","year":"1999","journal-title":"Nature"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.7150\/thno.46001","article-title":"Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis.","volume":"10","author":"Ye","year":"2020","journal-title":"Theranostics"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molcel.2017.11.025","article-title":"The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer.","volume":"69","author":"Jin","year":"2018","journal-title":"Mol Cell"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jnutbio.2018.10.007","article-title":"Fucoxanthin potentiates anoikis in colon mucosa and prevents carcinogenesis in AOM\/DSS model mice.","volume":"64","author":"Terasaki","year":"2019","journal-title":"J Nutr Biochem"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/sj.onc.1209493","article-title":"B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis.","volume":"25","author":"Boisvert-Adamo","year":"2006","journal-title":"Oncogene"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-12-22","article-title":"Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.","volume":"12","author":"Toricelli","year":"2013","journal-title":"Mol Cancer"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00432-023-05580-7","article-title":"The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.","volume":"150","author":"Hua","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"18135","DOI":"10.1007\/s00432-023-05486-4","article-title":"Combined signature of G protein-coupled receptors and tumor microenvironment provides a prognostic and therapeutic biomarker for skin cutaneous melanoma.","volume":"149","author":"Song","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"17897","DOI":"10.1007\/s00432-023-05483-7","article-title":"Integrative lactylation and tumor microenvironment signature as prognostic and therapeutic biomarkers in skin cutaneous melanoma.","volume":"149","author":"Zhu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2147\/CCID.S410723","article-title":"Construction and Identification of an NLR-associated prognostic signature revealing the heterogeneous immune response in skin cutaneous melanoma.","volume":"16","author":"Geng","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/jcb.26363","article-title":"Anoikis resistance and oncoviruses.","volume":"119","author":"Kakavandi","year":"2018","journal-title":"J Cell Biochem"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"8307","DOI":"10.1158\/0008-5472.CAN-07-1687","article-title":"A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis.","volume":"67","author":"Mawji","year":"2007","journal-title":"Cancer Res"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41598-018-37443-4","article-title":"Crabp2 promotes metastasis of lung cancer cells via HuR and integrin \u03b21\/FAK\/ERK signaling.","volume":"9","author":"Wu","year":"2019","journal-title":"Sci Rep"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"bqac171","DOI":"10.1210\/endocr\/bqac171","article-title":"CRABP2 is associated with thyroid cancer recurrence and promotes invasion via the integrin\/FAK\/AKT pathway.","volume":"163","author":"Liu","year":"2022","journal-title":"Endocrinology"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1016\/j.ejca.2009.04.001","article-title":"FASLG polymorphism is associated with cancer risk.","volume":"45","author":"Liu","year":"2009","journal-title":"Eur J Cancer"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1038\/s41388-019-0889-0","article-title":"Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation.","volume":"38","author":"Yao","year":"2019","journal-title":"Oncogene"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/bjc.2016.440","article-title":"Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor.","volume":"116","author":"Kim","year":"2017","journal-title":"Br J Cancer"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41419-018-0953-7","article-title":"NADPH oxidase 4 regulates anoikis resistance of gastric cancer cells through the generation of reactive oxygen species and the induction of EGFR.","volume":"9","author":"Du","year":"2018","journal-title":"Cell Death Dis"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1007\/s10620-019-05681-9","article-title":"Hepatitis B virus X protein induces SATB1 expression through activation of ERK and p38MAPK pathways to suppress anoikis.","volume":"64","author":"Tu","year":"2019","journal-title":"Dig Dis Sci"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02918248","article-title":"T-cell recognition of self peptides as tumor rejection antigens.","volume":"15","author":"Kawakami","year":"1996","journal-title":"Immunol Res"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2217\/imt-2017-0091","article-title":"Melanoma: a prototype of cancer-testis antigen-expressing malignancies.","volume":"9","author":"Faramarzi","year":"2017","journal-title":"Immunotherapy"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:41:19Z","timestamp":1746319279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037900","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}